

Chronic kidney disease and risk management: standards of care in diabetes-2025.

Guideline ID: 925

Published: 2025 Jan 1

American Diabetes Association (ADA)

American Diabetes Association Professional Practice Committee. Chronic kidney disease and risk management: standards of care in diabetes-2025. Diabetes Care. 2025 Jan 1;48(Supplement_1):S239-S251. [129 references] [PubMed](#)

[View Original Guideline](#)

Overview

Guideline Objective

- To provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care
- To offer guidance on the management, and risk management, of chronic kidney disease in patients with diabetes

Patient Population

Adult patients with diabetes

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Screening frequency and method
- Management interventions based on disease severity and risk of progression, including blood pressure control, angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), sodium–glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists (MRAs), reduction of urinary albumin, and protein intake
- Referral to nephrologist for evaluation

Note: Full recommendation statements have not been provided because this guideline does not meet [EGT's systematic review of the evidence criteria](#). Refer to the [original guideline](#) for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- [Introduction and Methodology: *Standards of Care in Diabetes—2025*](#); 2025 Jan 1.
- [Summary of Revisions: *Standards of Care in Diabetes—2025*](#); 2025 Jan 1.
- [Disclosures: *Standards of Care in Diabetes—2025*](#); 2025 Jan 1.

Implementation Tools

- Standards of Care App for [iOS](#) or [Android](#).
- [Continuing Medical Education](#).
- The [Original Guideline](#) includes the following:
 - Figure 11.1. Risk of CKD Progression, Cardiovascular Disease Risk, and mortality; Frequency of Visits; and Referral to Nephrology According to GFR and Albuminuria (p. S240)
 - Figure 11.2. Holistic Approach for Improving Outcomes in People with Diabetes and CKD (p. S245)

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.